[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"nChroma Bio\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":49},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100608333","phase-1-a-phase-12-open-label-single-and-multiple-ascending-dose-study-of-crma-1001-in-adults-with-chronic-hepatitis-b-100608333",false,"NCT07200193","A Phase 1\u002F2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B","A Multi-Center, Phase 1\u002F2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults With Chronic Hepatitis B","Inclusion Criteria:\n\n* Male\u002FFemale, weight 45-150 kg, age 18-64, inclusive\n* Diagnosed with Chronic Hepatitis B\n* On oral antiviral therapy\n* ALT and AST \\\u003C= 1.5 x ULN\n* Total bilirubin \\\u003C= ULN\n\nExclusion Criteria:\n\n* Significant hepatic fibrosis or cirrhosis\n* Current or prior liver disease other than HBV\n* Other protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years","64 Years",{"count":20,"type":21},66,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is an open-label study with single- and multiple-ascending dose arms followed by a dose expansion arm. The primary objective of the study is to determine the safety and tolerability of CRMA-1001 in adult participants with Chronic Hepatitis B. In addition, the pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of CRMA-1001 will be evaluated. CRMA-1001 is an epigenetic gene therapy delivered via intravenous (IV) infusion. Up to four dose levels will be tested. Participants will receive a single or multiple doses of CRMA-1001 and will remain on antiviral therapy during the dosing process.",[28],"Chronic Hepaititis B",[30,31,32,33,34,35],"CHB","Chronic hepatitis B","Chronic HBV","Chronic Hep B","Chronic hepatitis","HBV","RECRUITING","2026-06-12",{"date":39,"type":40},"2026-06-15","ACTUAL",{"date":42,"type":40},"2025-12-22",{"date":44,"type":21},"2032-12-31",{"name":46,"class":47},"nChroma Bio","INDUSTRY",4,""]